284 related articles for article (PubMed ID: 18772675)
1. Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa.
Shome D; Esmaeli B
Curr Opin Ophthalmol; 2008 Sep; 19(5):414-21. PubMed ID: 18772675
[TBL] [Abstract][Full Text] [Related]
2. [Lymphoproliferative lesions of the ocular adnexa. Differential diagnostic guidelines].
Coupland SE
Ophthalmologe; 2004 Feb; 101(2):197-215; quiz 216-7. PubMed ID: 15046030
[TBL] [Abstract][Full Text] [Related]
3. Metastatic tumors of the orbit and ocular adnexa.
Ahmad SM; Esmaeli B
Curr Opin Ophthalmol; 2007 Sep; 18(5):405-13. PubMed ID: 17700235
[TBL] [Abstract][Full Text] [Related]
4. Non-Hodgkin's lymphoma of the ocular adnexa.
Sasai K; Yamabe H; Dodo Y; Kashii S; Nagata Y; Hiraoka M
Acta Oncol; 2001; 40(4):485-90. PubMed ID: 11504308
[TBL] [Abstract][Full Text] [Related]
5. Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids): a prospective multiparametric analysis of 108 cases during 1977 to 1987.
Knowles DM; Jakobiec FA; McNally L; Burke JS
Hum Pathol; 1990 Sep; 21(9):959-73. PubMed ID: 2394438
[TBL] [Abstract][Full Text] [Related]
6. Ocular adnexal follicular lymphoma: a multicenter international study.
Rasmussen PK; Coupland SE; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; McKelvie P; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Heegaard S
JAMA Ophthalmol; 2014 Jul; 132(7):851-8. PubMed ID: 24763920
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
8. [Extranodal marginal zone lymphoma of the ocular adnexa].
Møller A; Specht L; Toft PB; Sjø LD
Ugeskr Laeger; 2008 Nov; 170(45):3660-3. PubMed ID: 18986616
[TBL] [Abstract][Full Text] [Related]
9. Emerging treatments for indolent lymphoma.
Cheson BD; Gregory SA; Marcus R
Clin Adv Hematol Oncol; 2007 May; 5(5 Suppl 8):1-9; quiz 11-2. PubMed ID: 17637594
[TBL] [Abstract][Full Text] [Related]
10. Imaging features of ocular adnexal lymphoproliferative disease.
Sullivan TJ; Valenzuela AA
Eye (Lond); 2006 Oct; 20(10):1189-95. PubMed ID: 17019418
[TBL] [Abstract][Full Text] [Related]
11. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
Esmaeli B; McLaughlin P; Pro B; Samaniego F; Gayed I; Hagemeister F; Romaguera J; Cabanillas F; Neelapu SS; Banay R; Fayad L; Wayne Saville M; Kwak LW
Ann Oncol; 2009 Apr; 20(4):709-14. PubMed ID: 19150940
[TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy for low-grade lymphomas: has the time come?
Cartron G; Solal-Céligny P
Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma.
Hatef E; Roberts D; McLaughlin P; Pro B; Esmaeli B
Arch Ophthalmol; 2007 Dec; 125(12):1663-7. PubMed ID: 18071119
[TBL] [Abstract][Full Text] [Related]
14. Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience.
Tuncer S; Tanyıldız B; Basaran M; Buyukbabani N; Dogan O
Curr Eye Res; 2015; 40(8):780-5. PubMed ID: 25247376
[TBL] [Abstract][Full Text] [Related]
15. Ocular adnexal lymphomas: five case presentations and a review of the literature.
Coupland SE; Hummel M; Stein H
Surv Ophthalmol; 2002; 47(5):470-90. PubMed ID: 12431695
[TBL] [Abstract][Full Text] [Related]
16. Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma.
Winter JN
Curr Opin Hematol; 2007 Jul; 14(4):360-8. PubMed ID: 17534162
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies in the diagnosis of lymphoproliferative diseases of the orbit and orbital adnexae.
Norton AJ
Eye (Lond); 2006 Oct; 20(10):1186-8. PubMed ID: 17019417
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy.
Bishton MJ; Hicks RJ; Westerman DA; Prince MH; Wolf M; Seymour JF
Haematologica; 2008 May; 93(5):789-90. PubMed ID: 18450737
[No Abstract] [Full Text] [Related]
19. Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck.
Manolopoulos L; Gomatos IP; Leandros E; Alevizos L; Georgiou N; Giotakis J; Ferekidis E
In Vivo; 2009; 23(3):475-8. PubMed ID: 19454517
[TBL] [Abstract][Full Text] [Related]
20. [Lymphoma of the ocular adnexa].
Rodríguez JN; Cañavate M; Amián A; Muñiz R; Prados D
Rev Clin Esp; 1994 Oct; 194(10):913-5. PubMed ID: 7800873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
